News
Evercore ISI Group Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $65
3 Apr 24
News, Price Target, Initiation, Analyst Ratings
RBC Capital Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $70
28 Mar 24
News, Price Target, Initiation, Analyst Ratings
TD Cowen Initiates Coverage On Jasper Therapeutics with Outperform Rating
18 Mar 24
News, Initiation, Analyst Ratings
Jasper Therapeutics Announces New Data Presented On Briquilimab Conditioning In Patients With Fanconi Anemia
15 Mar 24
Biotech, News, General
Oppenheimer Maintains Outperform on Jasper Therapeutics, Maintains $80 Price Target
7 Mar 24
News, Price Target, Analyst Ratings
Jasper Therapeutics Won Clearance for Initiation of its Phase 1b/2a BEACON Study of Subcutaneous Briquilimab in CSU, Phase 1b/2a SPOTLIGHT Study, Initiated a Phase 1 Trial of Briquilimab as Second-Line Therapy in Subjects with Myelodysplastic Syndromes
4 Mar 24
Government, News, Regulations
Jasper Therapeutics Reported FY23 EPS Loss of $(1.50), Cash Balance of $86.9M
4 Mar 24
Earnings, News
Jasper Therapeutics Presents Data From Preclinical Briquilimab Studies At The American Academy Of Allergy, Asthma, And Immunology Annual Meeting
23 Feb 24
Biotech, News, General
Over $15M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying
12 Feb 24
Long Ideas, News, Insider Trades, Markets, Trading Ideas
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
6 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Jasper Therapeutics Announces Pricing Of $50M Underwritten Offering Of 3.9M Shares Of Common Stock At A Price Of $12.95/Share
6 Feb 24
News, Offerings
Jasper Therapeutics Announces Preclinical Data Presentations At American Academy of Allergy, Asthma, and Immunology Annual Meeting
5 Feb 24
Biotech, News, Events, General
Press releases
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
News, Press Releases
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
21 Mar 24
News, Press Releases
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
19 Mar 24
Press Releases
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
4 Mar 24
Earnings, Press Releases
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
26 Feb 24
News, Press Releases
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
23 Feb 24
News, Analyst Ratings, Press Releases
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
7 Feb 24
News, Press Releases
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
6 Feb 24
News, Financing, Press Releases
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
5 Feb 24
News, Health Care, Press Releases
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Feb 24
Health Care, Press Releases